Industry comments on ANZTPA’s joint framework
25 February, 2013 by AusBiotechAusBiotech has made a submission on behalf of the biotechnology industry to the Australia New Zealand Therapeutic Products Agency’s (ANZTPA) discussion paper.
AtCor signs $800K contract expansion
25 February, 2013 by Tim DeanAtCor Medical (ASX:ACG) has expanded an existing contract to supply its SphygmoCor diagnostic to the tune of $800,000.
AtCor swings to profit
22 February, 2013 by Dylan Bushell-EmblingAtCor Medical (ASX:ACG) has reported its second ever half-year profit for 1H13 thanks to revenue growth and cost-cutting.
Movers & shakers: Another Farrell to head ResMed
21 February, 2013 by Tim DeanMick Farrell, son of Dr Peter Farrell, will take over as CEO of ResMed while his father transitions to non-executive chairman.
AusBiotech commends Productivity Commission’s draft report on compulsory licensing of patents
21 February, 2013 by AusBiotechAusBiotech has commended the “thorough work of commission and its December 2012 ‘Draft Report’ on Compulsory Licensing of Patents”.
PolyActiva $9.2m cash injection
20 February, 2013 by Tim DeanPolyActiva has raised $9.2m to further the development of its polymer drug delivery technology platform.
Patent review bonanza has industry under siege
20 February, 2013 by Dr Anna Lavelle, CEO, AusBiotechContinual government reviews of the intellectual property system are creating uncertainty in the life sciences industry that could hurt its future success.
Phosphagenics working on topical opioid patch
20 February, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) will bring a new product to trials after preclinical research showed oxycodone delivered with its TPM tech can provide pain relief without entering the blood.
Industry applauds Labor policy to aid innovation
19 February, 2013 by Tim DeanLabor announced yesterday its long-awaited policy on jobs and innovation, offering several reforms aimed at aiding innovative companies and biotechs.
Industry leaders’ views needed in the 2013 AusBiotech Industry Position Survey
18 February, 2013 by AusBiotechAusBiotech invites industry leaders to participate in the annual CEO Industry Position Survey 2013.
Novogen stocks soar following successful study
18 February, 2013 by Tim DeanNovogen (ASX:NRT) stocks have soared over 200% following a study that found its experimental drug CS-6 can kill not only cancer cells but also cancer stem cells.
Movers & shakers: Alchemia appoints new CEO
18 February, 2013 by Tim DeanAlchemia has appointed former Chief Financial Officer Charles Walker to the post of Chief Executive after Peter Smith stepped down following the failed Audeo Oncology demerger.
Gene patent upheld by Federal Court
18 February, 2013 by Tim DeanThe Federal Court has ruled in favour of Myriad Genetics and its patent of mutations in the BRCA1 gene, although some have expressed concern at the result.
BioDiem could help fight biological weapons
14 February, 2013 by Dylan Bushell-EmblingBioDiem (ASX:BDM) and a US army institute will collaborate on research into using antimicrobial BDM-I as a countermeasure for biological weapons including anthrax.
MRCF invests $1.25m in Helmedix to develop autoimmune therapies
14 February, 2013 by Tim DeanEarly-stage biopharma Helmedix has received $1.25m of start-up funding from the Medical Research Commercialisation Fund to develop therapies targeting autoimmune diseases.
